A Phase I, Prospective, Open-Labeled Study to Evaluate the Safety and Immunogenicity of MVC-COV1901

Medigen Vaccine Biologics Corp.1 site in 1 country45 target enrollmentOctober 7, 2020

ConditionsCOVID-19

Overview

Phase: Phase 1
Intervention: Not specified
Conditions: COVID-19
Sponsor: Medigen Vaccine Biologics Corp.
Enrollment: 45
Locations: 1
Primary Endpoint: Safety of MVC-COV1901
Status: Completed
Last Updated: 4 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This is a phase I prospective, open-labeled, single-center study to evaluate the safety and immunogenicity of MVC-COV1901.

Detailed Description

This is a phase I prospective, open-labeled, single-center study to evaluate the safety and immunogenicity of MVC-COV1901. This study is a dose escalation study with three separate arms for subjects at the age of ≥20 and \<50 years. The vaccination schedule for primary regimen consists of two doses of MVC-COV1901 for each study subject, administered by intramuscular (IM) injection 0.5mL in the deltoid region of non-dominant arm preferably 28 days apart, on Day 1 and Day 29. Subjects will receive a single booster vaccination of MVC-COV1901 on Day 209, 180 days after completion of the primary regimen.

Registry

clinicaltrials.gov

Start Date

October 7, 2020

End Date

December 6, 2021

Last Updated

4 years ago

Study Type

Interventional

Study Design

Sequential

Sex

All

Investigators

Sponsor

Medigen Vaccine Biologics Corp.

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Male or female healthy volunteer ≥20 and \<50 years of age
•Subject free of ongoing acute diseases or serious medical conditions (e.g. concomitant illness) such as cardiovascular (e.g. New York Heart Association grade III or IV), hepatic (e.g. Child-Pugh Class C), psychiatric condition (e.g. alcoholism, drug abuse), medical history, physical findings, or laboratory abnormality that in the investigator's opinion could interfere with the results of the trial or adversely affect the safety of the subject
•Female subject must be:
•Either of non-childbearing potential, i.e. surgically sterilized (defined as having undergone hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy; tubal ligation alone is not considered sufficient) or one year post-menopausal;
•Or, if of childbearing potential, must be abstinent or agree to use medically effective contraception from 14 days before screening to 30 days following last injection of study vaccines. Acceptable forms include:
•Implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS)
•Established use of hormonal methods (injectable, pill, patch or ring) combined with barrier methods of contraception: condom, or occlusive cap (diaphragm or cervical/vault caps) withspermicidal foam/gel/film/cream/suppository
•Have a negative pregnancy test
•Subject is willing and able to comply with all required study visits and follow-up required by this protocol
•Subject has no overseas travel within 14 days of screening and will not have any throughout the study period

Exclusion Criteria

•Receiving any investigational intervention either currently or within 30 days of first dose;
•Subject (particularly who is a healthcare worker) with previous known or potential exposure to SARS CoV-1 or 2 viruses (EXCEPT for those who have been tested negative and the 14-days self-managements/ home quarantines/ home isolations are completed), or received any other COVID-19 vaccine;
•Administration of any vaccine within 4 weeks of first dose;
•A BMI greater than or equal to 30 kg/m2;
•Subject with a history of hypersensitivity to any vaccine or a history of allergic disease or reactions likely to be exacerbated by any component of the MVC-COV1901;
•Administration of any blood product or intravenous immunoglobulin administration within 12 weeks of first dose;
•Pregnancy or breast feeding or have plans to become pregnant in 30 days after last injection of study vaccines;
•History of positive serologic test for HIV, hepatitis B surface antigen (HBsAg) or any potentially communicable infectious disease as determined by the investigator or Medical Monitor;
•Positive serologic test for hepatitis C (EXCEPTION: successful treatment with confirmation of sustained virologic response);
•Baseline evidence of kidney disease as measured by creatinine greater than 1.5 mg/dL;

Outcomes

Primary Outcomes

Safety of MVC-COV1901

Time Frame: Day 1 to 28 days after second vaccination

Incidence of solicited adverse events (AEs) after vaccination, Incidence of unsolicited AEs and other AEs after vaccination, Incidence of laboratory abnormality after vaccination, Incidence of adverse event of special interest (AESI) and serious adverse events (SAEs) after vaccination

Secondary Outcomes

Immunogenicity (neutralizing antibody titers and antigen specific binding antibody titers)(28 days and 180 days after the booster vaccination.)
Immunogenicity (antigen specific cellular immune responses)(28 days and 180 days after second vaccination)
Safety of MVC-COV1901(Day 1 to Day 209)